DolPHIN2 |

Mother-to-child transmission of HIV is preventable, and we have a duty to ensure the burden of HIV is not handed down across generations.

image source: pexels

The DolPHIN 2 programme investigates the safe and effective use of dolutegravir for women who present with untreated HIV in late pregnancy

The team at the Infectious Diseases Institute, Kampala

DolPHIN 2 is a multinational project led by the University of Liverpool which aims to reduce the rate of mother to child transmission (MTCT) of HIV through research into a new HIV drug called dolutegravir.

How we work

About DolPHIN 2

Read about the challenges that the DolPHIN 2 project seeks to address and why.

The DolPHIN 2 Consortium

Learn more about our multinational research consortium, comprising partners in Europe and sub-Saharan Africa.

Community Voices

Collaboration with the community is at the heart of DolPHIN 2. Click here to learn more about our community engagement, and to hear from some of our study participants.

Resources

11 Aug 2022

View all Resources

News

The Ugandan Team Celebrates World Breastfeeding Week

08 Aug 2019

DolPHIN-2 presents primary outcome analysis at CROI 2019

05 Mar 2019

DolPHIN-2 Study team's response to WHO's statement on the safety of dolutegravir in pregnancy

WHO released a statement on 18 May 2018 relating to a potential safety issue affecting women living with HIV using dolutegravir at the time of conception.

20 Jun 2018

View all News and Events

@UoLDolPHIN2 on Twitter

RT @CatrionaWaitt: Join us tomorrow for a presentation on the cost-effectiveness analysis within the @UoLDolphin2 trial. @UNITAID @livuniHLS @UCT_news @LSTMnews https://t.co/4CL5RdwCiy

5 months 2 weeks ago

RT @hivinteractions: New comedications added to the HIV site Dronedarone (Antiarrhythmics) Apalutamide (Cancer therapies) Bempedoic acid, Icosapent ethyl, Omega-3 fatty acids (Lipid Lowering Agents) Omega-3 fatty acids [in multivitamins] (Herbals/Supplements/Vitamins) Tirzepatide (Anti-diabetics)

6 months 6 days ago

DolPHIN2 investigator @CatrionaWaitt paper was mentioned at #ChivaConference during the #breastfeeding session. Check out the paper here https://t.co/o0H1kwQiDQ

6 months 2 weeks ago

RT @UNITAID: On #InternationalWomensDay, 8 March, Unitaid remains committed to addressing barriers to improve the lives and health of women in resource-constrained settings. Discover how Unitaid is bridging the gender divide through access to life-saving innovations: https://t.co/o2mhyMNqbo https://t.co/HiqKLimxNK

6 months 3 weeks ago

Laura Else from @LivUniISMIB will be presenting a poster at #CROI2023 today at 14 30 entitled Plasma & urine PK of #dolutegravir and #tenofovir to aid point-of-care testing. Stop by poster 527 to find out more

7 months 1 week ago

RT @covidDDIs: #CROI2023 Stop by poster 515 TODAY at 2h30 pm for a live discussion to learn more about the global collaboration to provide drug interaction guidance for nirmatrelvir/ritonavir @AlicePharmd @FionaMarra @alisonboyle_1 @geschena @KimScarsi

7 months 1 week ago

RT @AdellineTwimu: We successfully disseminated research findings to study participants. Thank you #DolPHIN2 team for making this happen! https://t.co/7FJrsOUl5M

7 months 1 week ago

RT @CatrionaWaitt: The @UoLDolphin2 participant feedback event reminded us all of the power of research to transform lives. Many emotional testimonials from participants of how involvement in the trial brought hope and healing. @UNITAID @TRIO_ARToptim @livuniHLS @IDIMakerere @radboudumc @UCT_news https://t.co/gX4zhmPdVT

7 months 1 week ago

RT @UNITAID: The @UoLDolphin2 programme investigates the safety and efficacy of dolutegravir in pregnant HIV+ women and their neonates. Find out more about the final 72-week postpartum results in @TheLancet: https://t.co/O9WmgzpDTu https://t.co/p59Zv3dlWC

9 months 1 week ago

We are recruiting a NIHR Academic Clinical Lecturer in Clinical Pharmacology and Therapeutics at University of Liverpool https://t.co/gRrI5C7LQ0

9 months 3 weeks ago

On #WorldAIDSDay we would like to thank all the participants for their time and commitment to the DolPHIN2 trial

10 months 2 days ago

RT @AdellineTwimu: Please follow the link below to join the forum through zoom; Dolutegravir in Pregnant HIV Mothers and their Noenates- (DoLPHIn 2) https://t.co/BW8V7GzVIn @IDIMakerere @UoLDolphin2 https://t.co/VNQIRcH5GS

11 months 1 day ago

The D2 Consortium

The DolPHIN 2 consortium is a multinational partnership comprising five research organisations and our funder, Unitaid.

DolPHIN2

Search

How we work

About DolPHIN 2

The DolPHIN 2 Consortium

Community Voices

Resources

Empower, Engage, Educate - Breastfeeding

Empower, Engage, Educate - Delivery

Empower, Engage, Educate - Male Involvement

Empower, Engage, Educate - Mumbwa

News

The Ugandan Team Celebrates World Breastfeeding Week

DolPHIN-2 presents primary outcome analysis at CROI 2019

DolPHIN-2 Study team's response to WHO's statement on the safety of dolutegravir in pregnancy

@UoLDolPHIN2 on Twitter

The D2 Consortium

University of Liverpool

Liverpool School of Tropical Medicine

Infectious Diseases Institute

University of Cape Town

Radboud University Medical Centre

Unitaid

Contact us

Follow us